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As humans age, they present to health carers with problems 
that reflect a combination of specific disease pathologies and 
individual features of the ageing process. Therapeutic use of 
prescription drugs is an important intervention in attempts to 
maintain the health of such individuals. This pharmacological 
intervention has a price, as an older person (aged 65 years or 
over) may be at greater risk of suffering iatrogenic adverse 
effects from the well-intentioned therapy.1,2
An injury resulting from the use of a drug is defined as 
an adverse drug event (ADE).3  The term ‘event’ rather than 
‘reaction’ or ‘effect’ is preferred as it is not always possible to 
ascribe certain causality to drug-related clinical presentations. 
Adverse drug events have been identified internationally as a 
top safety priority since the publication of the influential report 
by the United States Institute of Medicine in 2000, To Err is 
Human.4
As the beneficial effects of drugs are more widely 
documented, so older patients with a high burden of disease 
are prescribed increasing numbers of medications, not only for 
symptomatic relief (e.g. non-steroidal anti-inflammatory drugs 
(NSAIDs) and digoxin), but also to reduce mortality (e.g. beta-
blockers, angiotensin-converting enzyme (ACE) inhibitors and 
aspirin).5-8 The use of a greater number of medications increases 
the risk of an ADE.1,9 Longitudinal data from Australia show 
the rate of ADEs to be on the rise, with the age-standardised 
rate of ADE-related hospital stays increasing from 2.5/1 000 
person-years in 1981, to 12.9/1 000 person-years in 2002. The 
largest increase occurred in those aged 80+, a tenfold increase 
in men and a sevenfold increase in women.10
Ill public sector patients in the Western Cape Province enter 
the inpatient health system through admission from the EU 
(EU). Nearly all acute hospital admissions derive from the 
EU. International data on the presentation of older patients at 
an EU have identified ADEs to account for between 6.7% and 
14.2% of EU visits.11-15 Up to two-thirds of these ADEs may 
be preventable.16 An audit of patients presenting to an EU 
enables a determination of the impact of clinically significant 
events that may be causally attributable to a drug. However, 
little is known about ADEs in the South African EU setting. 
The present study was therefore conducted to determine the 
burden of ADEs in older patients presenting for care at an EU, 
to identify risk factors for these events and to ascertain which 
drugs pose a higher risk for ADEs.
Methods
A prospective cross-sectional study was conducted of patients 
aged 65 years and older who presented for treatment and care 
to the tertiary referral EU of Groote Schuur Hospital (GSH) in 
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Objective. To determine the burden and risk factors for adverse 
drug events (ADEs) in older patients.
Design. A prospective cross-sectional study.  
Methods. Patients (65 years and older) presenting to the tertiary 
Emergency Unit of Groote Schuur Hospital, Cape Town, 
between February and May 2005, were assessed for well-
established ADEs, as defined by the South African Medicines 
Formulary. Logistic regression models were fitted to determine 
drugs and other factors associated with the likelihood of 
developing ADEs.
Results. ADEs were identified in 104 of the 517 (20%) 
presentations. The most frequently involved drug classes were 
cardiovascular (34%), anticoagulant (27%), analgesic (19%) and 
antidiabetic (9%). Patients who developed ADEs were more 
likely to have five or more prescription drugs (p < 0.0001), 
more than three clinical problems (p = 0.001), require admission 
(p = 0.04), and report compliance with medication (p = 0.02) 
than those who did not. Drugs shown to independently confer 
increased risk of ADEs were angiotensin-converting enzyme 
inhibitors (RR = 2.6, 95% CI: 1.3 - 5.2, p = 0.009), non-steroidal 
anti-inflammatory drugs (RR = 4.1, 95% CI: 2.1 - 8.0, p < 0.0001) 
and warfarin (RR = 3.1, 95% CI: 1.6 - 6.3, p = 0.0014). 
Conclusion. ADEs contribute significantly to the burden of 
elderly care in the Emergency Unit. In a setting such as ours, 
increased pill burden and certain drug classes are likely to 
result in increased risk of ADEs in the older population group.
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Cape Town. All medical emergencies presenting to the hospital 
are assessed and stabilised in the unit. The study included all 
patients with complete data who presented to the EU between 
February and May 2005. 
Study information was collected using a standard proforma. 
Data collected included demographic data, detailed drug 
history including vitamin, herbal and over-the-counter (OTC) 
medications, a predefined clinical problem list, functional 
status for basic activities of daily living (BADLs) (independent 
or having dependence for one or more of the activities of 
bathing, eating, dressing or transfers), body habitus (as 
assessed by the primary physician and categorised as either 
obese, normal, thin or emaciated), medication compliance 
(self-reported by the patient or caregiver), number of repeat 
presentations during the study period, and clinical outcome. 
Acute trauma cases present to a different unit and were not 
included in the study.
For the purpose of this study an assessment was made by 
the primary physician and/or the principal investigator (BT) 
as to whether an ADE contributed to a patient’s presentation to 
the unit. Only well-established ADEs, as defined by the South 
African Medicines Formulary (6th edition), were considered. 
If an ADE was thought likely, its association was confirmed 
by causality grading. ADE causality was graded according 
to published recommendations which grades causation 
as: (i) certain if dechallenge and rechallenge information 
corroborates causation; (ii) probable if only dechallenge 
information corroborates causation; (iii) possible if competing 
explanations are plausible but less likely than drug causes; and 
(iv) unlikely if the timeline is improbable and an alternative 
explanation is more likely.3 ADEs of possible, probable and 
certain causality were considered as clinically important and 
analysed.
The study was approved by the Research Ethics Committee 
of the University of Cape Town’s Faculty of Health Sciences.
Statistical analysis
Univariate and multivariate models were fitted to determine 
factors associated with the likelihood of developing ADEs. 
The following factors were considered for inclusion in the 
analysis: age, sex, drug intake, body habitus, functional status 
for BADLs, number of clinical problems, compliance with 
medications and number of presentations during the study 
period. Continuous variables were categorised using their 
mean value. Factors identified to be significantly (p < 0.05) 
associated with the likelihood of having ADEs in the univariate 
models were used to build multivariate models. Categorical 
data were compared using the chi-square test.  Statistical 
analysis was performed using the SAS package, version 8 (SAS 
Institute Inc., Cary, North Carolina). 
Results
Older persons presenting to the EU during the study period 
comprised 17.5% of all patients assessed in the unit. Of these 
patients, 18 died before audit data could be obtained. The 
study included 517 patients. Mean age of the study population 
was 74 years (range 65 - 95 years). Women comprised 59% of 
the study individuals. 
The average number of clinical problems identified in the 
study population was 3.2 (range 0 - 6). The average number 
of prescription drugs used was 4 (range 0 - 10). The average 
number of OTC/vitamin/herbal preparations taken was 0.5 
(range 0 - 5).
ADEs were identified as contributing to 104 of the 517 
presentations, a prevalence of 20.1%. Of these 104 ADEs, 42 
were of probable causality, while 62 were of possible causality. 
In 14 presentations, multiple ADEs were identified as having a 
causal relationship to the patient’s presentation.
There was no significant difference in the patients who 
had ADEs, compared to those who did not, for the baseline 
characteristics of age, sex, body habitus, functional status for 
BADLs, use of OTC/vitamin/herbal preparations and the 
number of presentations made by each patient during the 
study period. Patients having ADEs were more likely to have 
five or more prescription medications (p < 0.0001), more than 
three clinical problems (p = 0.001) and be compliant with 
medication (p = 0.02) (Table I).  Patients having ADEs were 
more likely to be admitted (p = 0.04) and accounted for 74 
hospital admissions during the study period.
Cardiovascular drugs – beta-blockers (20 events), ACE 
inhibitors (10 events), digoxin (8 events), diuretics (3 events) 
and calcium channel blockers (2 events) –  accounted for 36% 
of the total ADEs. Antithrombotic agents – low-dose aspirin (19 
events), warfarin (12 events) and low-molecular-weight heparin 
(1 event) – caused 27% of ADEs. Analgesic drugs comprising 
NSAIDs (18 events) and opioids (4 events) accounted for 
18% of ADEs, while antidiabetic agents comprising oral 
hypoglycaemics (9 events) and insulin (1 event) accounted 
for 8%. The remaining ADEs were caused by central nervous 
system agents (5 events), immunosuppressive agents (5 
events), and antibiotics (1 event).
In a multivariate logistic regression model, the clinical 
problems that were independently associated with increased 
risk of having ADEs were atrial fibrillation (p = 0.014), diabetes 
(p = 0.011), gastro-intestinal (GI) bleeding (p < 0.0001), heart 
failure (p = 0.003) and hypertension (p = 0.05). The presence of 
stroke was negatively associated with an ADE (p = 0.007) (data 
not shown). 
Multivariate logistic regression analyses revealed that 
taking five or more drugs was significantly associated with 
the presence of an ADE (Table II), as well as ACE inhibitor, 
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warfarin and NSAID use (Table III). The apparent protective 
effect of non-compliance against an ADE was not significant in 
the multivariate analysis.
Discussion
The study findings confirm a high incidence of ADEs in the 
older patient population presenting to the EU. The rate of 
20% is among the highest reported in the literature, possibly 
because the study was actively seeking ADEs in a group of 
high-risk patients. However, it is well recognised that the 
protean manifestations and clinical presentation of ADEs in 
older patients make it possible that some events may still have 
been overlooked.
Table I. Baseline demographic and clinical characteristics of patients who had adverse drug events (ADEs) (N = 104) and those 
who did not (N = 413)
     Patients with ADE    Patients without ADE       
    N (%)    N (%)     p-value*
Age group (yrs)   
    65 - 74    62 (60)    236 (57) 
    75 - 84    35 (34)    143 (35) 
    > 85    7 (7)    34 (8) 
Sex            0.07
    Male    35 (34)    179 (43) 
    Female    69 (66)    234 (57) 
Body habitus   
    Obese     27 (26)    119 (30) 
    Normal                                                 23 (22)                        65 (16) 
    Thin    53 (51)    225 (54) 
    Emaciated   1 (1)    4 (1) 
Basic activity   
    Independent    71 (68)    282 (68.3) 
    Dependent    31 (30)    129 (31.2) 
    Unknown    2 (2)    2 (0.5) 
OTC use   
    Yes     48 (46.1)    156 (37.8) 
    No    56 (53.9)    257 (62.2) 
Prescription drug intake          < 0.0001
     < 5 drugs   38 (36)    267 (65) 
     ≥ 5 drugs   66 (64)    146 (35) 
Presence of clinical problems          0.001
     > 3 problems    47 (45)    259 (63) 
     ≤ 3 problems   57 (55)    156 (37) 
Compliance with medication          0.02
      Yes    93 (89)    329 (80) 
      No    11 (11)    84 (20) 
Number of presentations   
      1    99 (95)    326 (89.6) 
      2    3 (3)    35 (9.6) 
      3    2 (2)    2 (0.5) 
      4    0 (0)    1 (0.3)  
*Chi-square test.  
OTC = over-the-counter drugs.
Table II. Factors associated with the likelihood of having an ADE 
              Univariate analysis        Multivariate analysis
Factor    RR (95% CI) p-value*   RR (95% CI) p-value
≥ 5 drug intake    3.2 (2.0 - 5.0) < 0.0001   2.6 (1.6 - 4.1) < 0.001
> 3 clinical problems  2.0 (1.3 - 3.2) 0.001   1.5 (0.9 - 2.3) 0.11
Non-compliance   0.4 (0.2 - 0.8) 0.02   0.45 (0.2 - 0.1) 0.09
*Wald's statistic.
Univariate and multivariate logistic regression analysis.
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The large variation in the reported rates of ADEs in the 
EU (6.7 - 14.2%) may be attributable to methodological 
differences in the different studies on the causality assessment 
of ADEs. Recently attempts have been made to standardise 
ADE terminology and determination, and the present study 
followed these recommendations.3
The emergency room setting places a restriction on the level 
of causality assessment that can be achieved for any suspected 
ADE. In this study, levels of ‘possible’ or ‘probable’ causality 
were achieved. ‘Certain’ or ‘definite’ levels of causality 
require the presence of the rechallenge criterion to be satisfied. 
Rechallenge is often precluded in the EU setting for safety 
and efficiency reasons. The study showed that age is not a 
specific risk factor for ADEs; rather the number of concurrent 
prescription medications is the best predictor for an ADE. The 
number of coexistent diseases is directly related to the number 
of medications taken.
Drug classes associated with ADEs in this study have 
been consistently identified in similar EU studies for their 
risk of ADEs in older patients. In the literature the reported 
contribution to ADEs per drug class in the older population 
are analgesics (NSAIDs and opioids) (15 - 36%), cardiovascular 
drugs (including diuretics, beta-blockers, ACE inhibitors 
and digoxin) (5 - 41.8%), anticoagulants (7.9 - 13.3%) and 
hypoglycaemic agents (6.6 - 31%).2, 10-15,17,18 Interpretation of the 
contribution of each drug class to the total burden of ADEs 
requires caution. The use of no drugs results in no ADEs, while 
overuse of drugs clearly increases the risk. Any drug-related 
risk should be clearly weighed against drug-related benefit.
Accumulated trial data show that agents such as beta-
blockers, ACE inhibitors, aspirin, warfarin and antidiabetic 
medications have significant beneficial effects on morbidity 
and mortality.6,18-21  Despite optimal prescription and 
monitoring of these beneficial agents, a certain rate of ADEs 
will be observed. The number of beta-blocker-related ADEs 
(17%) in this study suggests that this class of drugs proven 
to be highly beneficial in ischaemic heart disease and cardiac 
failure may be incorrectly prescribed, despite an appropriate 
indication.6 In the public sector of the Western Cape atenolol 
and propanolol are the only beta-blockers available at primary 
and secondary level care. There is insufficient evidence that 
the use of atenolol or propranolol in heart failure confers the 
benefit reported with carvedilol or metoprolol. The practice 
of intra-drug class substitution in the older person in settings 
where original trial validated drugs are not available may 
increase the risk of ADEs.  
Other drugs used extensively in the older patient have 
not been shown to offer any survival benefit and are used 
mainly for symptomatic benefit only. These drugs include 
NSAIDs, digoxin and psychoactive agents like the tricyclic 
antidepressants. For these drugs the risks frequently outweigh 
any benefit, particularly when they are used in patients 
with significant comorbidity. Increasingly safer substitutes 
are available, for example using paracetamol for chronic 
pain, and the newer antidepressant agents in place of the 
tricyclic antidepressants. In the case of digoxin correct dosage 
prescription for corrected renal function, or substitution with a 
beta-blocker for heart rate control, may reduce ADEs.
A patient with an ADE is significantly more likely to 
require admission. ADEs contributed to 23% of older patient 
admissions to our hospital during the study period; this rate 
would account for over 250 admissions yearly at the current 
rate of ADEs. Data from the UK show that drugs contributed 
to 11% of hospital admissions of older patients. The data were 
obtained in the early 80s and 90s, and may not be comparable 
with recent data as a result of changing prescription trends.22
Our study is limited to one tertiary institution so the 
results may not be generalisable to other facilities. Other 
study weaknesses are that data were not available for some 
patients who presented to the EU who may have different 
characteristics or risk profiles. 
Despite the use of causality criteria, the diagnosis of the 
presence or absence of an ADE remains a subjective assessment 
and some ADEs may have been overlooked by the medical 
staff. The cross-sectional design of this study is another 
limitation, as patients in this study were not followed up 
beyond their acute assessment.
Table III. Drugs associated with the likelihood of having an ADE
            Univariate analysis                Multivariate analysis
Drug     RR (95% CI) p-value*    RR (95% CI)  p-value
ACE inhibitor   2.7 (1.8 - 4.2) < 0.0001   2.6 (1.3 - 5.2)  0.009
Beta-blocker      1.9 (1.2 - 3.0) 0.004   0.67 (0.3 - 1.3)  0.25
NSAIDs      3.4 (1.9 - 6.2) < 0.0001   4.1 (2.1 - 8.0)  < 0.0001
Anti-diabetic agents  1.6 (1.0 - 2.5) 0.05   1.2 (0.7 - 2.1)  0.53
Corticosteroids, oral  2.2 (1.0 - 4.9) 0.05   2.3 (0.9 - 5.4)  0.07
Diuretics    1.7 (1.1 - 2.7) 0.02   1.0 (0.6 - 1.7)  0.93
Warfarin    3.8 (2.0 - 7.3) < 0.0001   3.1 (1.6 - 6.3)  0.001
*Wald’s statistic.   
ACE = angiotensin-converting enzyme; NSAIDs = non-steroidal anti-inflammatory drugs.
Univariate and multivariate logistic regression analysis.
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A strength of this study is the prospective nature and 
manner in which ADEs were detected by the admitting 
physician and/or investigator while the patient was still 
present in the EU. This detection enabled the best evaluation at 
the time, rather than a judgement made at a later time where 
information on the event may be incomplete or cannot be 
extracted from clinical records.
An acceptable rate of ADEs for a drug class versus an 
unacceptable rate has not been determined and warrants 
further research, particularly in the context of older persons. 
Whether some ADEs may have been prevented with more 
careful monitoring also remains to be determined. In our 
resource-constrained health care system, cost-saving shortcuts 
could involve a reduction in monitoring; this approach may 
prove to be more costly in the longer term. 
ADEs are a common contributor to illness in the older 
person. When assessing an older patient, the possibility of an 
ADE contributing to the patient’s symptomatology should 
always be borne in mind.
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